INT76838

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 1.42
Pain Relevance 3.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Asprv1)
Anatomy Link Frequency
locus coeruleus 1
Asprv1 (Mus musculus)
Asprv1 - R2F (1)
Pain Link Frequency Relevance Heat
mu opioid receptor 1 99.84 Very High Very High Very High
narcan 6 99.82 Very High Very High Very High
Analgesic 4 99.82 Very High Very High Very High
nociceptor 2 99.82 Very High Very High Very High
opioid receptor 16 99.44 Very High Very High Very High
Locus ceruleus 7 97.48 Very High Very High Very High
Rheumatism 2 97.04 Very High Very High Very High
visual analogue scale 6 94.40 High High
Morphine 1 94.20 High High
antagonist 2 93.44 High High
Disease Link Frequency Relevance Heat
Rheumatic Diseases 2 97.04 Very High Very High Very High
Pain 4 93.16 High High
Rheumatoid Arthritis 8 90.64 High High
INFLAMMATION 2 86.12 High High
Disease 6 80.88 Quite High
Sleep Disorders 1 68.00 Quite High
Viral Infection 5 24.28 Low Low
Scoliosis 13 13.08 Low Low
Infection 19 9.60 Low Low
Pox Virus Infection 15 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The results indicate that TAPS binds to mu-opioid receptors on the cell membrane of neurons of the locus coeruleus to cause its inhibitory actions.
TAPS Binding (binds) of in locus coeruleus associated with locus ceruleus and mu opioid receptor
1) Confidence 0.36 Published 1998 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9698201 Disease Relevance 0.07 Pain Relevance 0.58
We recognize that the TAPS was developed from the information obtained from an analysis of the WRVAS and consider it to be derived from that instrument.
TAPS Binding (recognize) of
2) Confidence 0.24 Published 2010 Journal Scoliosis Section Body Doc Link PMC2852387 Disease Relevance 0.08 Pain Relevance 0
Furthermore, once the transport-permissive peptide, for example SV-NP, binds to interspecies TAPs, the phenylalanine residue at the N-terminus that is in contact with the human TAP counterpart may limit its binding capacity and, therefore, its transport.
TAPs Binding (binds) of
3) Confidence 0.18 Published 2005 Journal PLoS Pathogens Section Body Doc Link PMC1323471 Disease Relevance 0 Pain Relevance 0
The attenuated reduction of TAPS binding at the mu(2)-opioid receptor subtype in the presence of the stable guanosintriphosphate analog 5'-guanylylimidodiphosphate and sodium suggests a potential partial antagonist mode of action at this site.
TAPS Binding (binding) of associated with antagonist and opioid receptor
4) Confidence 0.14 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11282116 Disease Relevance 0 Pain Relevance 0.60
Receptor binding and biological activity of the dermorphin analog Tyr-D-Arg(2)-Phe-Sar (TAPS).
TAPS (R2F) Binding (binding) of associated with analgesic
5) Confidence 0.14 Published 2001 Journal Eur. J. Pharmacol. Section Title Doc Link 11282116 Disease Relevance 0 Pain Relevance 0.84
Both Buc and SASP were shown to be efficacious within 3 months after the start of treatment.
SASP Binding (efficacious) of
6) Confidence 0.06 Published 2009 Journal Mod Rheumatol Section Abstract Doc Link 19363607 Disease Relevance 0.64 Pain Relevance 0.55
Both Buc and SASP were shown to be efficacious within 3 months after the start of treatment.
SASP Binding (Both) of
7) Confidence 0.06 Published 2009 Journal Mod Rheumatol Section Abstract Doc Link 19363607 Disease Relevance 0.64 Pain Relevance 0.56

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox